Compare Neurocrine Biosciences Inc (NBIX) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nu Holdings Ltd — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Nu Holdings Ltd trades at $16.12 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 5.2× Neurocrine Biosciences Inc's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nu Holdings Ltd for 53 Days on average.
| NBIX | NU | |
|---|---|---|
Market Cap | $14.36B | $74.30B |
Volume | 1,237,180 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $185.50 | $18.76 |
52-Week Low | $123.10 | $11.60 |
Typical Hold Time | 23 Days | 53 Days |
Enterprise Value | $14.37B | $96.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
NU Holdings Ltd. (NU) trades at $15.38, down 1.28% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $10.63 billion and net income of $2.87 billion, though recent quarterly EPS results have been mixed. Analyst sentiment remains positive, with a consensus buy rating and a price target of $16.53.
The outlook for NU is supported by robust fundamentals and expanding customer base, but risks include credit exposure and acquisition speculation. The stock presents a growth opportunity if execution continues, yet investors must weigh high valuation multiples against potential macroeconomic headwinds in Latin American markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
